- Home
- SFWL vs BDTX Comparison
SFWL vs BDTX Comparison
Compare SFWL & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- BDTX
- Stock Information
- Founded
- SFWL 2001
- BDTX 2014
- Country
- SFWL China
- BDTX United States
- Employees
- SFWL N/A
- BDTX N/A
- Industry
- SFWL Trucking Freight/Courier Services
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SFWL Industrials
- BDTX Health Care
- Exchange
- SFWL Nasdaq
- BDTX Nasdaq
- Market Cap
- SFWL 80.8M
- BDTX 96.9M
- IPO Year
- SFWL 2023
- BDTX 2020
- Fundamental
- Price
- SFWL $0.98
- BDTX $1.57
- Analyst Decision
- SFWL
- BDTX Strong Buy
- Analyst Count
- SFWL 0
- BDTX 5
- Target Price
- SFWL N/A
- BDTX $15.60
- AVG Volume (30 Days)
- SFWL 10.3K
- BDTX 8.3M
- Earning Date
- SFWL 04-08-2025
- BDTX 03-06-2025
- Dividend Yield
- SFWL N/A
- BDTX N/A
- EPS Growth
- SFWL 4.79
- BDTX N/A
- EPS
- SFWL 0.13
- BDTX N/A
- Revenue
- SFWL $504,158,000.00
- BDTX N/A
- Revenue This Year
- SFWL N/A
- BDTX N/A
- Revenue Next Year
- SFWL N/A
- BDTX N/A
- P/E Ratio
- SFWL $7.43
- BDTX N/A
- Revenue Growth
- SFWL 24.75
- BDTX N/A
- 52 Week Low
- SFWL $0.81
- BDTX $1.51
- 52 Week High
- SFWL $2.23
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- SFWL 42.77
- BDTX 37.67
- Support Level
- SFWL $0.96
- BDTX $1.55
- Resistance Level
- SFWL $1.04
- BDTX $1.84
- Average True Range (ATR)
- SFWL 0.04
- BDTX 0.22
- MACD
- SFWL -0.00
- BDTX 0.00
- Stochastic Oscillator
- SFWL 23.56
- BDTX 5.88
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.